NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Abstract Introduction: Rotigotine is a dopamine receptor agonist commonly prescribed for Parkinson’s disease (PD) and restless leg syndrome. Although some common side effects have been previously reported, the rotigotine induced leukoderma is a very rare presentation. Case Presentation: Herein, we report a 37-year-old female with PD who developed depigmentation patches after one year of rotigotine application. Dermatology consultation reported drug-induced leukoderma, and topical steroid, narrow-band ultraviolet B, and ruxolitinib were administered. Her depigmentation spots started to improve while rotigotine was continued. Conclusions This case highlights the potential for ritogotine to induce skin depigmentation and emphasizes the need for continued observation and reporting of such adverse effects.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.